

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
VIRTUAL PLATFORM**

January 19, 2022

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for October 20, 2021 meeting  
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/DURB\\_10-20-21\\_meeting\\_transcript~edit.pdf](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/DURB_10-20-21_meeting_transcript~edit.pdf)
- IV. Review of draft meeting summary for October 20, 2021 meeting (pages 3-7)
- V. Secretary’s report (page 8)
- VI. Old Business
  - A. Review of updated PA denials report for ALL plans (page 9)
  - B. Review of utilization of drugs/products with DURB-recommended protocols (page 10)
  - C. “Dear Prescriber” letter/newsletter on ivermectin (pages 11-12)
- VII. New Business
  - A. Addendum for PCSK9 Inhibitors protocol (pages 13-17)
  - B. Addendum for Spravato® (esketamine) protocol (pages 18-19)
  - C. Proposed protocol for Gamifant® (emapalumab-lzsg) [pages 20-21]
  - D. Proposed Protocol for Nitisinone products (pages 22-23)
  - E. Proposed protocol for Lucemyra® (lofexidine) [page 24]
  - F. Proposed protocol for Paxlovid® (nirmatrelvir/ritonavir) – Emergency Use Authorization (EUA)
  - G. Proposed protocol for molnupiravir - EUA
- VIII. A. Informational Highlights/Reports
  - 1. Gainwell Technologies/NJ HMO 3<sup>rd</sup> Quarter 2021 Prior Authorization Report (page 25)
  - 2. Summary of DURB Action Items (pages 26-27)
  - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
    - FFS top drugs:  
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS\\_Top\\_Drugs\\_Report\\_Nov\\_2021.xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS_Top_Drugs_Report_Nov_2021.xlsx)
    - MCO top drugs:  
[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/MCO\\_Top\\_Drugs\\_Report\\_Oct\\_2021.xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/MCO_Top_Drugs_Report_Oct_2021.xlsx)

FFS category:

[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS\\_Top\\_Drugs\\_by\\_Category\\_Nov\\_2021.xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS_Top_Drugs_by_Category_Nov_2021.xlsx)

MCO category:

[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/MCO\\_Top\\_Drugs\\_by\\_Category\\_Oct\\_2021.xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/MCO_Top_Drugs_by_Category_Oct_2021.xlsx)

(b) Antiviral drugs by amount paid

[https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS\\_Antiviral\\_Drugs\\_Nov\\_2021.xlsx](https://www.state.nj.us/humanservices/dmahs/boards/durb/agendas/1-2022/FFS_Antiviral_Drugs_Nov_2021.xlsx)

B. Medication information:

1. COVID-19 Vaccines information

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19

<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.

3. New Jersey COVID-19 Information Hub (continuously updated)

<https://covid19.nj.gov/>

4. Know Your Treatment Options for COVID-19 – FDA

<https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19>

IX. Referenced Materials:

- A. Addendum for Duchenne muscular dystrophy products – approved October 2021 (pages 28-30)
- B. Protocol for Aduhelm® (aducanumab) – approved October 2021 (pages 31-32)
- C. Protocol for Bronchitol® (mannitol) – approved October 2021 (page 33)